Net debt/EBITDA společnosti SinoMab BioScience
Jaká je hodnota metriky Net debt/EBITDA společnosti SinoMab BioScience?
Hodnota metriky Net debt/EBITDA společnosti SinoMab BioScience Limited je -3.99
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na HKSE ve srovnání se společností SinoMab BioScience
Čemu se věnuje společnost SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Firmy s metrikou net debt/ebitda podobnou společnosti SinoMab BioScience
- Hodnota metriky Net debt/EBITDA společnosti Tripadvisor Dl ,001 je -4.01
- Hodnota metriky Net debt/EBITDA společnosti Organto Foods je -4.01
- Hodnota metriky Net debt/EBITDA společnosti DKSH je -4.01
- Hodnota metriky Net debt/EBITDA společnosti Ninety One PLC je -4.01
- Hodnota metriky Net debt/EBITDA společnosti Carebook Technolgies Inc je -4.01
- Hodnota metriky Net debt/EBITDA společnosti New York Times Co je -4.00
- Hodnota metriky Net debt/EBITDA společnosti SinoMab BioScience je -3.99
- Hodnota metriky Net debt/EBITDA společnosti Ameriprise je -3.99
- Hodnota metriky Net debt/EBITDA společnosti Martello Technologies je -3.99
- Hodnota metriky Net debt/EBITDA společnosti Renishaw Plc je -3.98
- Hodnota metriky Net debt/EBITDA společnosti Rizhao Port Jurong Co je -3.98
- Hodnota metriky Net debt/EBITDA společnosti Acerus Pharmaceuticals je -3.98
- Hodnota metriky Net debt/EBITDA společnosti Canopy Growth je -3.98